J. Andersson

1.2k total citations · 1 hit paper
8 papers, 866 citations indexed

About

J. Andersson is a scholar working on Oncology, Molecular Biology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, J. Andersson has authored 8 papers receiving a total of 866 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Oncology, 2 papers in Molecular Biology and 2 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in J. Andersson's work include HER2/EGFR in Cancer Research (3 papers), Monoclonal and Polyclonal Antibodies Research (2 papers) and Glycosylation and Glycoproteins Research (1 paper). J. Andersson is often cited by papers focused on HER2/EGFR in Cancer Research (3 papers), Monoclonal and Polyclonal Antibodies Research (2 papers) and Glycosylation and Glycoproteins Research (1 paper). J. Andersson collaborates with scholars based in Sweden. J. Andersson's co-authors include L. E. Rutqvist, L. Tabár, Nils Bjurstam, A. Lindgren, S. Rydén, G Fagerberg, Jan Frisell, L. Nyström, Lars‐Gunnar Larsson and Stig Wall and has published in prestigious journals such as The Lancet, Annals of Oncology and European Journal of Cancer.

In The Last Decade

J. Andersson

7 papers receiving 804 citations

Hit Papers

Breast cancer screening with mammography: overview of Swe... 1993 2026 2004 2015 1993 200 400 600

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
J. Andersson Sweden 7 688 250 112 107 92 8 866
P C Allgood United Kingdom 15 603 0.9× 200 0.8× 98 0.9× 102 1.0× 72 0.8× 21 833
APM Forrest United Kingdom 10 616 0.9× 352 1.4× 145 1.3× 63 0.6× 52 0.6× 11 800
Xiao-Ming Xie China 14 386 0.6× 260 1.0× 114 1.0× 49 0.5× 65 0.7× 22 629
Jane E. Brock United States 16 369 0.5× 315 1.3× 219 2.0× 55 0.5× 85 0.9× 42 727
TJ Anderson United Kingdom 7 408 0.6× 220 0.9× 106 0.9× 48 0.4× 54 0.6× 8 548
S A Narod Canada 12 548 0.8× 315 1.3× 114 1.0× 96 0.9× 60 0.7× 20 1.0k
Petra M. M. Beemsterboer Netherlands 13 516 0.8× 158 0.6× 82 0.7× 60 0.6× 53 0.6× 20 920
Stephen Duffy United Kingdom 11 784 1.1× 250 1.0× 192 1.7× 126 1.2× 110 1.2× 15 1.3k
Yiwey Shieh United States 11 393 0.6× 212 0.8× 82 0.7× 38 0.4× 64 0.7× 21 674
Henrik Hellborg Sweden 18 667 1.0× 355 1.4× 111 1.0× 103 1.0× 107 1.2× 24 1.2k

Countries citing papers authored by J. Andersson

Since Specialization
Citations

This map shows the geographic impact of J. Andersson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J. Andersson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J. Andersson more than expected).

Fields of papers citing papers by J. Andersson

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J. Andersson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J. Andersson. The network helps show where J. Andersson may publish in the future.

Co-authorship network of co-authors of J. Andersson

This figure shows the co-authorship network connecting the top 25 collaborators of J. Andersson. A scholar is included among the top collaborators of J. Andersson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J. Andersson. J. Andersson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

8 of 8 papers shown
1.
Andersson, J., Lena Larsson, Sigrid Klaar, et al.. (2005). Worse survival for TP53 (p53)-mutated breast cancer patients receiving adjuvant CMF. Annals of Oncology. 16(5). 743–748. 46 indexed citations
2.
Andersson, J., Barbro Linderholm, Jonas Bergh, & Göran Elmberger. (2004). HER-2/neu (c-erbB-2) Evaluation in Primary Breast Carcinoma by Fluorescent In Situ Hybridization and Immunohistochemistry With Special Focus on Intratumor Heterogeneity and Comparison of Invasive and In Situ Components. Applied immunohistochemistry & molecular morphology. 12(1). 14–20. 35 indexed citations
4.
Andersson, J., Barbro Linderholm, Birgitta Lindh, et al.. (2002). A Population-based Study on the First Forty-Eight Breast Cancer Patients Receiving Trastuzumab (Herceptin®) on a Named Patient Basis in Sweden. Acta Oncologica. 41(3). 276–281. 11 indexed citations
5.
Lindahl, Thomas, Georg Engel, Johan Ahlgren, et al.. (2000). Can Axillary Dissection be Avoided by Improved Molecular Biological Diagnosis?. Acta Oncologica. 39(3). 319–326. 12 indexed citations
6.
Raqib, Rubhana, et al.. (1998). FAS-MEDIATED APOPTOSIS AND PERFORIN-INDUCED CELL DEATH IN SHIGELLOSIS. Journal of Pediatric Gastroenterology and Nutrition. 27(2). 249–249. 1 indexed citations
7.
Nyström, L., Stig Wall, L. E. Rutqvist, et al.. (1993). Breast cancer screening with mammography: overview of Swedish randomised trials. The Lancet. 341(8851). 973–978. 707 indexed citations breakdown →
8.
Johanson, Chris E., et al.. (1970). Deep venous thrombosis treated with a standard dosage of streptokinase.. PubMed. 136(3). 181–9. 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026